Mebicar IC tab. 0.3 g, in a pack of 20

Storage:

active substance: mebikar;

1 tablet contains mebicar 300 mg (0.3 g);

excipients: methylcellulose, calcium stearate.

Pharmaceutical form. Tablets.

Main physicochemical properties: tablets of white color, flat-cylindrical shape, with a chamfer; on one surface of the tablet the trademark of the company is applied, on the other surface of the tablet there is a dash.

Pharmacotherapeutic group.

Psychostimulants, attention deficit hyperactivity disorder (ADHD), and nootropics. Other psychostimulants and nootropics. Mebikar.

ATX code N06B X21.

Indication.

Neuroses and neurosis-like conditions accompanied by irritability, emotional lability, feelings of anxiety and fear; to improve the tolerability of neuroleptics or tranquilizers in order to eliminate the somatovegetative and neurological side effects caused by them; cardialgias of various genesis (not related to coronary heart disease).

As part of the complex therapy of nicotine dependence as a means that reduces the urge to smoke.

Contraindication.

Individual hypersensitivity to the components of the medicinal product.

Interaction with other medicinal products and other types of interactions.

Mebikar IS can be combined with antipsychotics, tranquilizers (benzodiazepines), hypnotics, antidepressants and psychostimulants.

Features of application.

The drug should be used with caution in arterial hypotension, liver and kidney function disorders.

Addiction, dependence and withdrawal syndrome when using mebikar have not been established.

Use during pregnancy or breastfeeding.

Mebikar penetrates well into all tissues and body fluids.

The medicine should not be used during pregnancy or breastfeeding due to the lack of sufficient data on the safety of using mebikar during this period.

The ability to influence the speed of reaction when driving vehicles or other mechanisms.

You should be careful when driving vehicles, because the use of mebikar can cause a decrease in blood pressure and weakness.

Method of application and dosage.

Use the medicine internally regardless of food intake. The dosage depends on the individual characteristics of the patient and the therapeutic purpose of the drug.

The usual dose is 300–600 mg 2–3 times a day. If necessary, the dose can be increased. The maximum single dose is 3 g, the maximum daily dose is 10 g. The duration of the treatment course is from several days to 2–3 months.

As part of the complex treatment of nicotine addiction, the drug should be used at 600–900 mg 3 times a day daily for 5–6 weeks.

It is not necessary to reduce the dose of the drug for elderly patients and patients with liver failure.

Dose adjustment has not been studied in patients with renal insufficiency. The drug should be prescribed with caution to such patients.

If the next dose was not taken on time one or more times, the course of treatment should be continued according to the previously prescribed scheme.

Children.

The drug is not intended for use by children.

Overdose.

The drug is low-toxic. With a significant overdose, side effects may increase (including allergic reactions, dyspeptic disorders, weakness, temporary decrease in blood pressure and body temperature).

Treatment: it is necessary to wash the stomach and apply generally accepted methods of detoxification.

No specific antidote is known.

Expiry date. 4 years.

Storage conditions.

Store in the original packaging at a temperature not higher than 25 °C.

Keep out of the reach of children.

Packaging.

10 tablets in a blister; 2 blisters in a pack.

Leave category. Without a prescription.

Producer.

“INTERKHIM” Limited Liability Company.

The location of the manufacturer and the address of the place of its activity.

Ukraine, 65025, Odesa, 21st km. 40-A, Starokyivska road.